John Dawson - ALLIANCE PHARMA CEO, Executive Director
| DVL Stock | EUR 0.38 0.01 2.56% |
CEO
John Dawson is Chief Executive Officer Executive Director of Alliance Pharma Plc. John founded Alliance in 1996. He gained multidisciplinary experience in the pharmaceutical industry over thirty years. John held various senior roles at Sandoz as director of finance and administration and deputy managing director. John has a BSc and an MSc from the London Business School.
Similar Executives
| Found 1 records | CEO Age | ||
| Jeffrey Quartermaine | Perseus Mining Limited | N/A | |
ALLIANCE PHARMA Leadership Team
Elected by the shareholders, the ALLIANCE PHARMA's board of directors comprises two types of representatives: ALLIANCE PHARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ALLIANCE. The board's role is to monitor ALLIANCE PHARMA's management team and ensure that shareholders' interests are well served. ALLIANCE PHARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ALLIANCE PHARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sarah Robinson, Company Secretary | ||
| David Cook, Independent Non-Executive Director | ||
| Janice Timberlake, Director of Human Resources | ||
| Andrew Franklin, Finance Director, Director | ||
| John Dawson, CEO, Executive Director | ||
| Stephen Kidner, Other - Operations Director | ||
| Dan Thomas, Other - Business Development Director | ||
| Anthony Booley, Executive Director | ||
| Andrew Smith, Non-Executive Director | ||
| Nigel Clifford, Independent Non-Executive Director | ||
| Margaret Boulton, Other - Medical and Regulatory Affairs Director | ||
| Thomas Casdagli, Non-Executive Director | ||
| Peter Butterfield, Executive Director |
ALLIANCE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ALLIANCE PHARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 400.06 M | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 1.39 X | |||
| Total Debt | 116.06 M | |||
| Number Of Employees | 13 | |||
| Market Capitalization | 653.93 M | |||
| Total Asset | 503.49 M | |||
| Z Score | 3.0 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 503.49 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ALLIANCE PHARMA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ALLIANCE PHARMA's short interest history, or implied volatility extrapolated from ALLIANCE PHARMA options trading.
Pair Trading with ALLIANCE PHARMA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ALLIANCE PHARMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALLIANCE PHARMA will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ALLIANCE PHARMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ALLIANCE PHARMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ALLIANCE PHARMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ALLIANCE PHARMA to buy it.
The correlation of ALLIANCE PHARMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ALLIANCE PHARMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ALLIANCE PHARMA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ALLIANCE PHARMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ALLIANCE PHARMA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for ALLIANCE Stock analysis
When running ALLIANCE PHARMA's price analysis, check to measure ALLIANCE PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ALLIANCE PHARMA is operating at the current time. Most of ALLIANCE PHARMA's value examination focuses on studying past and present price action to predict the probability of ALLIANCE PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ALLIANCE PHARMA's price. Additionally, you may evaluate how the addition of ALLIANCE PHARMA to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |